No Data
New Novus: 2024 Annual Report
New Novus: 2024 Annual Report Summary
"Burned" over 0.8 billion yuan in R&D expenses, CSPC Innovation Pharmaceutical experiences a decline in revenue and net profit | Interpretations
① The functional foods and ingredients business segment experienced a decrease in main business revenue while research and development expenses significantly increased, resulting in declines in revenue and Net income for CSPC Innovation Pharmaceutical in 2024. ② In 2024, the company achieved certain results in the field of Innovative Drugs.
CSPC Innovation Pharmaceutical (300765.SZ): The net income for the fiscal year 2024 is 53.7263 million yuan, with a proposed dividend of 0.2 yuan per share.
Gelonghui on March 20th丨CSPC Innovation Pharmaceutical (300765.SZ) announced its annual report for 2024, revealing that the company achieved revenue of 1.981 billion yuan, a year-on-year decrease of 21.98%; Net income attributable to Shareholders of the listed company was 53.7263 million yuan, down 87.63% year-on-year; Net income attributable to Shareholders of the listed company, after deducting non-recurring gains and losses, was 42.3419 million yuan, a year-on-year decrease of 94.31%; Basic EPS was 0.0384 yuan; It is proposed to distribute a cash dividend of 0.20 yuan (including tax) for every 10 shares to all Shareholders.
While Institutions Invested in CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Benefited From Last Week's 13% Gain, Public Companies Stood to Gain the Most
Soochow Securities Starts CSPC Innovation Pharmaceutical at Buy